(Q43989091)

English

Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jeanne Kowalski

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

W A Hall

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

A V Petrova

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

C W Hardy

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

B Saka

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

J W Shelton

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

M D Warren

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

B G Pantazides

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

K Gandhi

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

D A Kooby

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

B F El-Rayes

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

C A Staley

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

N Volkan Adsay

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

W J Curran

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

J C Landry

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

S K Maithel

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

D S Yu

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

0 references

publication date

25 November 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

33

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

5450-5456

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

47

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24276239%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

https://scigraph.springernature.com/pub.10.1038/onc.2013.488

0 references

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

CHD5 is a tumor suppressor at human 1p36

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

CHD5 is down-regulated through promoter hypermethylation in gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Mutation screening of CHD5 in melanoma-prone families linked to 1p36 revealed no deleterious coding or splice site changes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Distinct high-profile methylated genes in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

CHD5, a tumor suppressor that is epigenetically silenced in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Chd5 requires PHD-mediated histone 3 binding for tumor suppression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Mechanisms of CHD5 Inactivation in neuroblastomas

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.488

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43989091&oldid=2105354433"